Pharmacodynamics
Ethosuximide is an anticonvulsant drug that belongs to the succinimides. The mechanism of action has not been definitively established; among other properties, an inhibitory effect on GABA degradation was found.
Indications for use of Suxilep
Pycnoleptic absence seizures, as well as complex and atypical seizures.
Note. To avoid the development of generalized tonic-clonic seizures, which often aggravate the course of complex and atypical seizures, a combination of ethosuximide with anticonvulsants (for example, primidone, phenobarbital) can be used. Additional prevention of generalized tonic-clonic seizures can be carried out without exception in the case of pycnoleptic absence seizures in school-age children.
Myoclonic-astatic small seizures (petit mal).
Juvenile myoclonic seizures (impulsive petit mal seizures).
Contraindications for the use of Suxilep
Hypersensitivity to the components of the drug.
Use in children under 6 years of age is not recommended due to the impossibility of precise dosing of this dosage form.
With caution:
If there is a history of mental illness (risk of developing corresponding side effects – anxiety, hallucinatory symptoms); increased risk of myelotoxicity.
Liver and/or renal failure.
